Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema
Monday, September 25, 2023Takeda TSE NYSETAK today announced the European Medicines Agencys EMA Committee for Medicinal Products for Human Use CHMP has recommended the approval of lanadelumab trade name TAKHZYRO for the routine prevention of Hereditary Angioedema HAE in patie...
Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients
Monday, September 25, 2023Merck NYSE MRK known as MSD outside of the United States and Canada and Eisai today provided updates on two Phase trials LEAP and LEAP evaluating KEYTRUDA
BioInvent recruits first patient in Phase 2a trial of single agent BI-1808 for the treatment of advanced malignancies
Monday, September 25, 2023BioInvent International AB BioInvent Nasdaq Stockholm BINV a biotech company focused on the discovery and development of novel and firstinclass immunemodulatory antibodies for cancer immunotherapy
Debiopharm And Sunrock Biopharma Partner To Advance Antibody Drug Conjugates For Hard-to-treat Cancers
Friday, September 22, 2023Debiopharm wwwdebiopharmcom a privatelyowned Swissbased biopharmaceutical company aiming to establish tomorrows standardofcare to cure cancer and infectious diseases today announced an exclusive option and license agreement with SunRock Biopharma
NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients
Friday, September 22, 2023NewAmsterdam Pharma Company NV Nasdaq NAMS or NewAmsterdam or the Company a clinicalstage biopharmaceutical company developing oral nonstatin medicines for patients at high risk of cardiovascular disease with residual elevation of lowdensity lipoprot...
Merck Enters Two Strategic Collaborations to Strengthen AI-driven Drug Discovery
Thursday, September 21, 2023Merck a leading science and technology company today announced two new strategic drug discovery collaborations aimed at harnessing powerful artificial intelligence AIdriven design and discovery capabilities further advancing the companys research eff...
Merck Enters Two Strategic Collaborations to Strengthen AI-driven Drug Discovery
Thursday, September 21, 2023Merck a leading science and technology company today announced two new strategic drug discovery collaborations aimed at harnessing powerful artificial intelligence AIdriven design and discovery capabilities further advancing the companys research eff...
SPT Labtech Empowers UK Genomics Community by Opening its Doors for the firefly® Roadshow
Wednesday, September 20, 2023SPT Labtech a global leader in the design and development of automated instrumentation and consumables for life science applications will host the UK leg of the firefly roadshow at the Companys headquarters in Melbourn Cambridgeshire on September in...
Evaxion expands its preclinical bacterial vaccine portfolio in collaboration with a leading pharmaceutical company
Wednesday, September 20, 2023Evaxion Biotech AS NASDAQ EVAX Evaxion or the Company a clinicalstage biotechnology company specializing in the development of immunotherapies based on on AI today announced the launch of a new research program EVXB an AIengineered vaccine candidate...
Hyku Biosciences Launches With $56M to Advance its Covalent Medicines Platform to Expand the Boundaries of Drug Discovery
Wednesday, September 20, 2023Hyku Biosciences Inc Hyku today announced its launch with million in seed financing to develop precision covalent medicines in oncology Hyku is deploying an innovative chemoproteomics platform that selectively disarms diseasecausing proteins by cova...
